Search results
Results from the WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following is a list of publicly traded companies having the greatest market capitalization, sometimes described as their "market value": [1] Market capitalization is calculated by multiplying the share price on a selected day and the number of outstanding shares on that day.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
It's a truism in the stock market that winners tend to keep winning. For pharmaceutical companies, making good on that axiom requires a lot of hard work to develop new medicines, and to find ways ...
Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates. Large Cap Pharma, Biotech Stocks Down on Regulatory ...
In this article, we take a look at the top 10 vaccine companies in the world. You can skip our detailed analysis of the vaccine production developments, and go to the Top 5 Vaccine Companies in ...
The security U.S. listing must be exclusively on the NASDAQ National Market (unless the security was dually listed on another U.S. market prior to January 1, 2004 and has continuously maintained such listing). The issuer of the security must be classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals.